Delos Capital, founded in 2013, is a private equity fund that partners with strong management teams and strategic owners to invest in lower middle market companies.
Employees: 1-10
Portfolio 13
| Date | Name | Website | Total Raised | Location |
| 16.06.2026 | Rejoni | rejoni.com | $50M | United Sta... |
| 12.06.2023 | ECCOGENE 诚... | eccogene.com | $25.2M | China, Sha... |
| 16.05.2023 | Ensoma | ensoma.com | $258M | United Sta... |
| - | FCA | fcapackaging.com | - | United Sta... |
| - | Innovative... | icpgroup.com | - | United Sta... |
| - | Interstate... | interstaterestoration.com | - | United Sta... |
| - | Exela Tech... | exelatech.com | - | United Sta... |
| - | Onelife Fi... | onelifefitness.com | - | United Sta... |
| - | HOP Energy... | hopenergy.com | - | - |
| - | United Fle... | unitedfleamarkets.com | - | United Sta... |
Show more
Mentions in press and media 11
| Date | Title | Description |
| 18.06.2026 | Rejoni Secures $25M for Uterine Health Innovation, Juveena System Nears Launch | Rejoni, a leading women's health company, secured $25 million. This substantial financing fuels the advanced development and market introduction of its Juveena Hydrogel System. Juveena aims to revolutionize uterine healing. It targets the r... |
| 16.06.2026 | Rejoni Secures $25 Million To Advance Juveena Hydrogel System Toward FDA Approval And Commercial Launch | Rejoni, a clinical-stage women’s health company focused on biomaterial therapies, announced the closing of a $25 million financing round to support the development and commercialization of the Juveena Hydrogel System. The financing included... |
| 16.06.2026 | Rejoni Raises $25M in Funding | Rejoni, Inc., a Bedford, MA-based clinical-stage company which specializes in uterine health, raised $25M in funding. Backers included Clavyst Bio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventur... |
| 26.09.2025 | Ensoma Secures $53M to Accelerate In Vivo Stem Cell Gene Therapies | Ensoma has secured $53 million in a pivotal funding round. This capital infusion accelerates its groundbreaking work in one-time, in vivo stem cell therapies. A primary goal involves progressing the Phase 1/2 clinical trial for EN-374, spec... |
| 23.09.2025 | Ensoma Raises $53M in Funding | Ensoma, a Boston, MA-based in vivo hematopoietic stem cell (HSC) engineering company, raised $53M in funding. Backers included Gilead (Nasdaq: GILD), which has also appointed an executive to the Ensoma board of directors as part of its inve... |
| 23.09.2025 | Avenzo: $60 Million Series B Secured For Developing Oncology Therapies | Avenzo Therapeutics, a biotechnology company focused on developing new cancer treatments, has announced the closing of a $60 million Series B funding round. This latest investment follows a previous $386 million raised through its Series A ... |
| 23.09.2025 | Ensoma: $53 Million Secured To Advance Stem Cell Therapies And Global Clinical Impact | Ensoma, a biotechnology company focused on transforming medicine through one-time, in vivo stem cell therapies, has announced the closing of a $53 million funding round. This investment comes from a group of leading investors who have previ... |
| 12.07.2022 | Transworld M&A Advisors assists Rycor HVAC on its merger with HOP Energy | Transworld M&A Advisors Peter Berg, Managing Director of Transworld M&A Advisors and Jennifer Fox, Partner of Transworld Business Advisors of Boston advised Rycor Peter Berg, Jen Fox and the entire Transworld team did an excellent j... |
| 14.11.2019 | Comvest Credit Partners Announces Investment in HOP Energy, LLC | West Palm Beach, FL – (November 8, 2019) – Comvest Credit Partners (“Comvest”) has acted as Administrative Agent and Sole Lender in providing a $45.0 million senior secured term loan (the “Financing”) to HOP Energy, LLC (“HOP Energy”), a po... |
| 09.04.2018 | Delos Capital Raises $23.9M For Sophomore Fund | New York City-based Delos Capital, a lower middle market private equity firm, has raised $23.9 million for its second fund, according to an SEC filing. No target was listed in the document. |
Show more